“takeda” Archives

in
Entry Author Date Location
Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials 08/11/20 National
VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs 07/09/20 San Diego
Cerevance Raises $45M to Advance Brain Disease Research & Development 04/14/20 Boston
Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data 02/26/20 San Diego
After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020 01/21/20 San Diego
Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration 01/07/20 Boston
Why Steve Kafka Left Third Rock Ventures for Up-and-Comer Section 32 11/05/19 San Diego
Reneo Pharma Launches with $50M to Target Energy-Depleting Diseases 05/20/19 San Diego
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More 05/10/19 National
Takeda Unites San Diego Operations At New ‘Biotech-Style’ R&D Center 04/29/19 San Diego
Servier Licenses CureMatch Tech for Custom Cancer Drug Treatments 03/15/19 San Diego
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again 02/14/19 National
Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M 02/06/19 San Diego
Morphic Nets Another $80M For Integrin Drugs & First Human Tests 09/25/18 Boston
FDA Clears Mersana to Restart Cancer Drug Trial With New Safeguards 09/17/18 Boston
Millendo Therapeutics Goes Public With OvaScience Reverse Merger 08/09/18 Detroit Ann Arbor
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future? 08/08/18 San Francisco
OUTBio, a Biopharma LGBTQ Group, Grows Fast & Ponders Its Future 07/26/18 Boston
Mindstrong Adds $15M for Tech That Predicts Mental Health Changes 06/14/18 San Francisco
Eying Clinical Trials, Shattuck Labs Adds $46M for Immunotherapy R&D 05/30/18 Texas
Shine, BrightStar, Understory & More: This Week’s WI Watchlist 02/20/18 Wisconsin
Wave, Takeda Target RNA Technology at Neuro Diseases With $230M Pact 02/20/18 Boston
Stem Cell Firm Cellular Dynamics to Provide Heart Cells to Takeda 02/13/18 Wisconsin
Gilman’s Next CEO Trick: Taming CAR-T Cells With Obsidian 12/06/17 Boston
Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More 08/04/17 National
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
With $75M Haul, Ovid Continues Flurry of Biotech IPOs 05/04/17 New York
With Ovid IPO, Ex-Teva CEO Levin Pitches Neuro Drug Plan to Wall Street 04/11/17 New York
To Infinity and Beyond: Julian Adams on Missteps and His New Job 04/03/17 Boston
Page 1 of 4 next page »